The global fibrotic diseases treatment market is anticipated to grow at a CAGR of 6.0% during the forecast period (2022-2028). Fibrosis is a distinctive biochemical characteristic of majority of chronic inflammatory diseases. It is scarring that results out of the accumulation of excess extracellular matrix components. If highly progressive, the fibrotic process eventually leads to organ malfunction and mortality. The market growth is majorly attributable to the growing incidences of fibrosis and the growing R&D activities related to its therapeutics. In addition to this, the growing cases of idiopathic pulmonary fibrosis is also anticipated to spur the demand for fibrotic diseases treatment, thereby driving the market growth. Idiopathic pulmonary fibrosis is a rare and serious disease that primarily affects human lungs and leads to the building up of scar tissue within the lungs. For instance, as per the National Institutes of Health (NIH) in the US alone, about 30,000 to 40,000 new cases of idiopathic pulmonary fibrosis are found each year.
The projection of this disease is estimated to grow substantially on a global level. For instance, the new cases of this fibrosis are projected to be 10.7 cases per 100,000 person-years for males and 7.4 cases per 100,000 person-years for females across the globe. The prevalence of idiopathic pulmonary fibrosis is estimated to be 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females. Some key players operating in the market include Boehringer Ingelheim International GmbH, Genentech, Inc., and Apotex Inc., among others.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Fibrotic Diseases Treatment Market at: https://orionmarketreports.com/request-sample/?id=101150&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Treatment
- By Application
- By End-User
- By Distribution Channel
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Boehringer Ingelheim International GmbH, Genentech, Inc., and Apotex Inc., among others.
A full report Fibrotic Diseases Treatment Market of is available at: https://orionmarketreports.com/fibrotic-diseases-treatment-market/101150/
Global Fibrotic Diseases Treatment Market Report by Segment
By Treatment
- Drugs
- Pirfenidone (Esbriet)
- Nintedanib (OFEV)
- Therapy
- Surgery
By Application
- Idiopathic Pulmonary Fibrosis
- Cutaneous Fibrosis,
- Renal Fibrosis
- Hepatic Cirrhosis
- Others
By End-User
- Hospitals
- Specialty Clinics
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
